Pulse Biosciences(PLSE) - 2025 Q4 - Annual Results

Exhibit 99.1 Endocardial Catheter AF Ablation Surgical AF Ablation Soft Tissue Ablation "2025 was a highly productive year for Pulse Biosciences as we achieved notable milestones in each of our market development programs. Most importantly, we have advanced our nsPFA platform into late-stage clinical development to treat atrial fibrillation in both electrophysiology and cardiac surgery, receiving FDA IDE approvals to initiate both pivotal studies," said Paul LaViolette, CEO of Pulse Biosciences. "I am thril ...